Fort Lee, NJ — November 4, 2025 — Leads & Copy — Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported its third quarter 2025 financial results and provided a business update, including the initiation of the NXP900 Phase 1b program, which aims to provide preliminary evidence of clinical efficacy in patients with advanced cancers. The program’s combination portion is expected to start by year-end.
Nuvectis Pharma’s NXP900 Phase 1a dose escalation study was successfully completed, highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosing.
The company also completed a NXP900 clinical drug-drug interaction study in healthy volunteers supporting our strategy for combination therapy. Poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics highlight the emerging clinical profile of NXP900 and provide further support for the biomarker-based patient selection strategy.
As of September 30, 2025, cash and cash equivalents were $35.4 million, expected to support operations into 3Q-2027. The net loss for the quarter was $7.5 million.
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, believes the company’s cash position and focus on efficient operations will enable it to achieve key milestones for the NXP900 Phase 1b program.
Ron Bentsur, Chairman, Chief Executive Officer, and President, rbentsur@nuvectis.com
Kevin Gardner, LifeSci Advisors, kgardner@lifesciadvisors.com
Source: Nuvectis Pharma, Inc.
